Tag: FOR

Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　 announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.

Combined platform unifies multimodal AI-powered physical threat detection with patented emergency response technology, creating real-time situational intelligence across K-12 schools, and senior living.

Pepe Dollar ($PEPD) gains momentum as a best crypto presale while PEPETO nears fundraising completion during expanding Q3 2026 altcoin activity

Chengdu, China, June 01, 2026 (GLOBE NEWSWIRE) -- JIADE LIMITED (Nasdaq: JDZG) (“JIADE” or the “Company”), a provider of one-stop comprehensive education support services for adult education institutions through its subsidiaries in the People’s Republic of China, today announced that the Company has completed the additional closing of $8.64 million of its Class A ordinary shares in a registered direct offering (the “Additional Closing”), following an initial closing of $3.36 million of its Class A ordinary shares, which closing occurred on May 7, 2026. Pursuant to a certain securities purchase agreement, dated May 4, 2026 (the “Agreement”), entered into by and among the Company and certain purchasers (the “Purchasers”), the Company agreed to sell an aggregate of up to $12.0 million of its Class A ordinary shares in the registered direct offering.